Key statistics for the anti-infectives market can be summarised as follows:
- ca85% of the current clinical pipeline is for the treatment of Gram positive infections
- A lean pipeline of new drugs targeting problems of hospital and community acquired Gram negatives exists
- 2 million nosocomial infections in the US per annum - problem pathogens include MRSA & Gram negatives
- Community based infections are increasing with a market of $17-18 billion (problem pathogen Streptococci & Klebsiella)
- Treatment of hospital infections is usually by intravenous administration costing $6.7Bn in 2005
- Treatment of fungal infections – $5-6 billion
Against this backdrop it is Aquapharm's intention to focus on developing new compounds based on the novelty of marine microbial chemistry against Gram negative and/or Gram positive organisms, with the problem pathogens considered to be Pseudomonas, Acinetobacter, Klebsiella, Streptococci, Staphylococci and Enterococci.